sutrobio.com (STRO): Rasio rega marang prakiraan pendapatan
Sutro Biopharma, Inc. (STRO) is optimizing costs through the automation of its California plant. GURU.Markets provides this chart based on the forward price-to-sales ratio, where the current parameter is 3.50. Business revenues are based on the sale of its antibody-drug conjugate platform. Pipeline development relies on strategic R&D alliances with industry behemoths to co-fund clinical trials.
Rincian analitis perusahaan Sutro Biopharma, Inc (STRO)
- rega saham lan target rega konsensus:
- data kapitalisasi bursa:
- indikator nilai buku ekuitas:
- indikator total utang lan likuiditas perusahaan:
Rasio Total Utang marang Ekuitas Sutro Biopharma, Inc.|STRO - Rasio silihan jangka dawa marang modal|Utang jangka cendhak marang modal Sutro Biopharma, Inc.|STRO - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku Sutro Biopharma, Inc|STRO - Utang jangka dawa|Utang jangka cendhak perusahaan Sutro Biopharma|Rasio cepet sutrobio.com
- data bathi bisnis lan rasio investasi:
STRO - Bathi resik|Bathi sing dikarepake Sutro Biopharma, Inc.|STRO - Kapitalisasi marang bathi resik|Prakiraan rega marang bathi Sutro Bio|STRO - Rega marang bathi kanthi panyesuaian wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Sutro Biopharma, Inc|STRO - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Sutro Biopharma|STRO - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan sutrobio.com|STRO - Wutah bathi resik saben siji saham kanggo taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Sutro Biopharma, Inc.
- rincian pendapatan lan dodolan:
Ringkesan analisis perusahaan:Sutro Biopharma STRO
Monetization of the antibody conjugate platform through contracts with pharma behemoths establishes the base of expected revenues, which are compared against the current market capitalization of Sutro Biopharma (STRO) when calculating the business's forward P/S ratio. This indicator measures the premium investors are willing to pay per unit of future revenue, allowing an analysis of the forward P/S to distinguish fundamental undervaluation from temporary market volatility.
Analisis pesaing
ImmunityBio - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Immunocore Holdings IMCR|JANX - Rasio rega marang prakiraan pendapatan|RCUS (Arcus Corp) - Kapitalisasi marang prakiraan pendapatan|Zymeworks Inc. (ZYME) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep tangotx.com (TNGX)|Multiplikator forward rega marang pendapatan IOVA|IMTX - Prakiraan rega marang pendapatan|Multiplikator forward rega marang pendapatan XNCR (Xencor Corp)|Rasio rega marang pendapatan sing dikarepake CMPX|Multiplikator Forward P/S REPL (Replimune Group, Inc.)|Rega forward marang dodolan LYEL|Innate Pharma - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Pyxis Oncology, Inc.|cgen.com (CGEN) - Rasio rega marang prakiraan pendapatan|IO Biotech Inc. - Rega forward marang dodolan|INKT (MiNK Therapeutics, Inc.) - Multiplikator Forward P/S|Multiplikator Forward P/S Werewolf|Rasio rega marang prakiraan pendapatan Immix Biopharma, Inc. (IMMX)|ALXO: Rega mangsa ngarep marang pendapatan|Cue Biopharma, Inc. - Multiplikator forward rega marang pendapatan|PDS Biotech (PDSB) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|SONN - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake MAIABiotech.com MAIA|LIMN (Liminatus Pharma LLC) - Multiplikator forward rega marang pendapatan|LAVA Therapeutics (LVTX) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan NXTC|LPTX (Leap Tx) - Rasio rega marang pendapatan sing dikarepake|Rasio rega marang prakiraan pendapatan Intensity Therapeutics (INTS)|SNSE (senseibio.com) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Theriva Biologics TOVX|Gritstone bio Inc. (GRTS) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|KA: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan NEXI (NexImmune Corporation)|TSBX: Multiplikator Forward P/S|VCNX (vaccinex.com) - Rasio rega marang prakiraan pendapatan|HARP (Harpoon Therapeutics, Inc.) - Multiplikator Forward P/S
